Clinical Trials for Mesothelioma Patients: Cisplatin, Pemetrexed and Bevacizumab Inclusion Criteria
Read the inclusion criteria for a clinical trial being conducted to study the effects of Cisplatin, Pemetrexed and Bevacizumab for patients who have been diagnosed with mesothelioma. Please note: this information is provided by Weitz & Luxenberg for informational purposes only.
Inclusion criteria: 5.2.1 Patients must have histologically proven malignant mesothelioma (epithelial, sarcomatoid, or mixed subtype) not amenable to curative surgery or radiotherapy. Eligible sites of origin include the pleura, peritoneum, and tunica vaginalis. 5.2.2 Patient’s disease must not be amenable to curative treatment with surgery. Evidence of gross unresectability will include but not be limited to direct extension into the chest wall, mediastinal or hilar lymphadenopathy, pulmonary or cardiac function that is inadequate to tolerate resection, and sarcomatoid or mixed histology. 5.2.3 Patients must be > 18 years old 5.2.4 Patients must have measurable disease. Adequate organ function and functional status
Mesothelioma & Asbestosis Mortalities Across the US: 1979-2001 (c/o EWG)
“We have seen first-hand how asbestos has wreaked havoc on Americans working in naval shipyards, automobile plants, and the construction industry. Most often this is through their employers’ conscious choice for profits over a worker's health.”
-- Joseph Patrick Williams, a trial attorney in the Asbestos Litigation department of Weitz & Luxenberg
Contact information for Vitamin B12 study on mesothelioma patients